Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

5(83.3%)

Early Phase 1

1(16.7%)

6Total

N/A(5)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06763692Not ApplicableNot Yet Recruiting

Low Intensity Focused Ultrasound for Parkinson's Disease

Role: lead

NCT06218706Not ApplicableRecruiting

LIFU for Treatment for Refractory Opioid Use Disorder

Role: lead

NCT05469009Early Phase 1Active Not Recruiting

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

Role: lead

NCT06485687Not ApplicableActive Not Recruiting

Low Intensity Focused Ultrasound for Binge Eating Disorder

Role: lead

NCT05997030Not ApplicableRecruiting

Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

Role: lead

NCT04440891Not ApplicableWithdrawn

Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease

Role: lead

All 6 trials loaded